GABAergic neuroactive steroids: A new frontier in bipolar disorders?

Behavioral and Brain Functions

Volumn 8, Issue , 2012, Pages

  Carta, Mauro Giovanni ^a   Bhat, Krishna M ^b   Preti, Antonio ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 3ALPHA HYDROXYSTEROID DEHYDROGENASE; ALLOTETRAHYDRODEOXYCORTICOSTERONE; ANDROSTANE DERIVATIVE; ANDROSTANEDIOL; ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLOZAPINE; DEOXYCORTICOSTERONE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ETIOCHOLANONE; FLUOXETINE; HYDROXYSTEROID DEHYDROGENASE; LAMOTRIGINE; MOOD STABILIZER; NEUROSTEROID; OLANZAPINE; PRASTERONE SULFATE; PREGNANE DERIVATIVE; PREGNENOLONE; PREGNENOLONE SULFATE; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR; SEROTONIN UPTAKE INHIBITOR; STEROID 5ALPHA REDUCTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

ANESTHESIA; BIPOLAR DISORDER; BRAIN CORTEX; CATAMENIAL EPILEPSY; DISEASE EXACERBATION; DISEASE SEVERITY; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; EPILEPSY; GENDER; HIPPOCAMPUS; HUMAN; HYPOMANIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MENOPAUSE; MOOD; NONHUMAN; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PROTEIN BINDING; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEDATION; SINGLE NUCLEOTIDE POLYMORPHISM; STEROID BLOOD LEVEL; STEROIDOGENESIS;

ANIMALS; BIPOLAR DISORDER; BRAIN; GABA MODULATORS; GABAERGIC NEURONS; HUMANS; NEUROTRANSMITTER AGENTS; RECEPTORS, GABA-A;

EID: 84871132137     PISSN: None     EISSN: 17449081     Source Type: Journal    
DOI: 10.1186/1744-9081-8-61     Document Type: Review

References (104)

1. Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA, Welnberger DR, Karayiorgou M, Guidotti A, Gingrich J, Akbarian S, Buchanan RW, Lieberman JA, Conn PJ, Haggarty SJ, Law AJ, Campbell B, Krystal JH, Moghaddam B, Saw A, Caron MG, George SR, Allen JA, Solis M. Advancing drug discovery for schizophrenia. Ann N Y Acad Sci 2011, 1236:30-43. 10.1111/j.1749-6632.2011.06216, 22032400.
2. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food And Drug Administration. PLoS Med 2008, 5(2):e45. 10.1371/journal.pmed.0050045, 2253608, 18303940.
3. Turner EH, Knoepflmacher D, Shapley L. Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. PLoS Med 2012, 9(3):e1001189. Epub 2012 Mar 20, 10.1371/journal.pmed.1001189, 3308934, 22448149.
4. Goff DC, Hill M, Freudenreich O. Treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry 2011, 72:e13. 10.4088/JCP.9096tx6cc, 21527119.
5. Barbui C, Kikkert M, Mazzi MA, Becker T, Bindman J, Schene A, Nosè M, Helm H, Thornicroft G, Tansella M. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence. Psychopathology 2009, 42(5):311-7. 10.1159/000232973, 19672133.
6. George I. Papakostas, maurizio fava predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorderDialogues. Clin Neurosci 2008, 10(4):439-451.
7. Carta MG, Angst J. Epidemiological and clinical aspects of bipolar disorders: controversies or a common need to redefine the aims and methodological aspects of surveys. Clin Pract Epidemol Ment Health 2005, 1(1):4.
8. Sullivan PF. The Psychiatric GWAS Consortium: big science comes to psychiatry. Neuron 2010, 68:182-186. 10.1016/j.neuron.2010.10.003, 2991765, 20955924.
9. Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nature Neurosci. 2010, 13:1161-1169. 10.1038/nn.2647, 20877280.
10. Häfner H, an der Heiden W, Behrens S, et al. Causes and consequences of the gender difference in age at onset of schizophrenia. Schizophr Bull 1998, 242:6-12.
11. Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003, 28:17-54.
12. Leung A, Chue P. Sex differences in schizophrenia: a review of the literature. Acta Psychiatr Scand 2000. Suppl 2000, 401:3-38.
13. Cascio MT, Cella M, Preti A, Meneghelli A, Cocchi A. Gender and duration of untreated psychosis: a systematic review and meta-analysis. Early Interv Psychiatry 2012, 6(2):115-27. 10.1111/j.1751-7893.2012.00351.x, 22380467.
14. Grossman LS, Harrow M, Rosen C, Faull R, Strauss GP. Sex differences in schizophrenia and other psychotic disorders: a 20-year longitudinal study of psychosis and recovery. Compr Psychiatry 2008, 49:523-529. 10.1016/j.comppsych.2008.03.004, 2592560, 18970899.
15. Haro JM, Novick D, Bertsch J, Karagianis J, Dossenbach M, Jones PB. Cross-national clinical and functional remission rates: worldwide schizophrenia outpatient health outcomes (W-SOHO) study. Br J Psychiatry 2011, 199:194-201. 10.1192/bjp.bp.110.082065, 21881098.
16. Reicher-Rossler A, Hafner H, Dutsch-Strobel A, et al. Further evidence for a specific role of estradiol in schizophrenia?. Biol Psychiatry 1994, 36:492-494. 10.1016/0006-3223(94)90649-1, 7811850.
17. Seeman M, Lang M. The role of estrogens in schizophrenia gender differences. Schizophr Bull 1990, 16:185-194. 10.1093/schbul/16.2.185, 2197713.
18. Thorup A, Petersen L, Jeppesen P, et al. Gender differences in young adults with first-episode schizophrenia spectrum disorders at baseline in the Danish OPUS study. J Nerv Ment Dis 2007, 195:396-405.
19. Waraich P, Goldner EM, Somers JM, Hsu L. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry 2004, 49(2):124-38.
20. Diflorio A, Jones I. Is sex important? Gender differences in bipolar disorder. Int Rev Psychiatry 2010, 22(5):437-52. 10.3109/09540261.2010.514601, 21047158.
21. Baulieu EE, Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. J Endocrinol 1996, 150:S221-S239.
22. Agís-Balboa RC, Pinna G, Zhubi A, Maloku E, Veldic M, Costa E, Guidotti A. Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proc Natl Acad Sci USA 2006, 103(39):14602-7. 10.1073/pnas.0606544103, 1600006, 16984997.
23. Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA. International union of pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 2006, 58(4):773-781. 10.1124/pr.58.4.8, 17132854.
24. Scarpin KM, Graham JD, Mote PA, Clarke CL. Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. Nucl Recept Signal 2009, 7:e009. 2807635, 20087430.
25. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol 2008, 70:165-90. 10.1146/annurev.physiol.70.113006.100518, 18271749.
26. Woolley CS, McEwen BS. Estradiol regulates hippocampal dendritic spine density via an N-methyl-D-aspartate receptor-dependent mechanism. J Neurosci 1994, 14(12):7680-7.
27. Appelgren LE. Sites of steroid hormone formation. Autoradiographic studies using labelled precursors. Acta Physiol Scand Suppl 1967, 301:1-108.
28. Seyle H. The stress of life 1956, New York: Mac Graw Hill.
29. Holzbauer M. Ovarian secretion of steroids with central depressant actions. J Physiol 1971, 215(1):16P-17P. 1331812, 5103914.
30. Sherwin BB. Estrogen and cognitive functioning in women. Endocr Rev 2003, 24(2):133-151. 10.1210/er.2001-0016, 12700177.
31. Kompoliti K. Estrogen and movement disorders. Clin Neuropharmacol 1999, 22(6):318-326.
32. Craft RM, Ulibarri C, Leitl MD, Sumner JE. Dose- and time-dependent estradiol modulation of morphine antinociception in adult female rats. Eur J Pain 2008, 12(4):472-9. 10.1016/j.ejpain.2007.07.014, 17869144.
33. Corpechot C, Robel P, Axelson M, Sjovall J, Baulieu EE. Characterization and measurement of dehydroepiandrosterone sulfate in rat brain. Proc Natl Acad Sci USA 1981, 78:4704-4707. 10.1073/pnas.78.8.4704, 320231, 6458035.
34. Do Rego JL, Seong JY, Burel D, Leprince J, Luu-The V, Tsutsui K, Tonon MC, Pelletier G, Vaudry H. Neurosteroid biosynthesis: enzymatic pathways and neuroendocrine regulation by neurotransmitters and neuropeptides. Front Neuroendocrinol 2009, 30(3):259-301. 10.1016/j.yfrne.2009.05.006, 19505496.
35. Melcangi RC, Celotti F, Castano P, Martini L. Differential localization of the 5 alpha-reductase and the 3 alpha-hydroxysteroid dehydrogenase in neuronal and glial cultures. Endocrinology 1993, 132(3):1252-9. 10.1210/en.132.3.1252, 8440186.
36. Petratos S, Hirst JJ, Mendis S, Anikijenko P, Walker DW. Localization of p450scc and 5α-reductase type-2 in the cerebellum of fetal and newborn sheep. Developmental Brain Research. 2000, 123:81-86. 10.1016/S0165-3806(00)00076-6, 11020552.
37. Stoffel-Wagner B. Neurosteroid metabolism in the human brain. Eur J Endocrinol 2001, 145(6):669-79. 10.1530/eje.0.1450669, 11720889.
38. Stoffel-Wagner B, Watzka M, Steckelbroeck S, Ludwig M, Clusmann H, Bidlingmaier F, Casarosa E, Luisi S, Elger CE, Beyenburg S. Allopregnanolone serum levels and expression of 5 alpha-reductase and 3 alpha-hydroxysteroid dehydrogenase isoforms in hippocampal and temporal cortex of patients with epilepsy. Epilepsy Res 2003, 54(1):11-9. 10.1016/S0920-1211(03)00036-6, 12742591.
39. Patte-Mensah C, Kappes V, Freund-Mercier MJ, Tsutsui K, Mensah-Nyagan AG. Cellular distribution and bioactivity of the key steroidogenic enzyme, cytochrome P450side chain cleavage, in sensory neural pathways. J Neurochem 2003, 86(5):1233-46. 10.1046/j.1471-4159.2003.01935.x, 12911631.
40. Guennoun R, Fiddes RJ, Gouézou M, Lombès M, Baulieu EE. A key enzyme in the biosynthesis of neurosteroids, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase (3 beta-HSD), is expressed in rat brain. Brain Res Mol Brain Res 1995, 30(2):287-300. 10.1016/0169-328X(95)00016-L, 7637579.
41. Nothdurfter C, Rammes G, Baghai TC, Schüle C, Schumacher M, Papadopoulos V, Rupprecht R. Translocator protein (18 kDa) as a target for novel anxiolytics with a favourable side-effect profile. J Neuroendocrinol 2012, 24(1):82-92. 10.1111/j.1365-2826.2011.02166.x, 21609361.
42. Reddy DS. Neurosteroids: endogenous role in the human brain and therapeutic potentials. Prog Brain Res 2010, 186:113-37. 3139029, 21094889.
43. Rupprecht R, Reul JM, Trapp T, van Steensel B, Wetzel C, Damm K, Zieglgänsberger W, Holsboer F. Progesterone receptor-mediated effects of neuroactive steroids. Neuron 1993, 11(3):523-30. 10.1016/0896-6273(93)90156-L, 8398145.
44. Reddy DS. Pharmacology of endogenous neuroactive steroids. Crit Rev Neurobiol 2003, 15:197-234.
45. Olsen RW, Siegart W. International union of pharmacology. Subtypes of gamma aminobutyric acid a receptors: classification on the basis of subunit composition, pharmacology and function. Pharmacol Rev 2008, 60:243-260. 10.1124/pr.108.00505, 2847512, 18790874.
46. McKernan RM, Whiting PJ. Which GABAA receptor subtypes really occur in the brain?. Trends Neurosci 1996, 19:139-143. 10.1016/S0166-2236(96)80023-3, 8658597.
47. Botta P, Radcliffe RA, Carta M, Mameli M, Daly E, Floyd KL, Deitrich RA, Valenzuela CF. Modulation of GABAA receptors in cerebellar granule neurons by ethanol: a review of genetic and electrophysiological studies. Alcohol 2007, 41(3):187-99. Epub 2007 May 23, 10.1016/j.alcohol.2007.04.004, 1986723, 17521847.
48. Reddy DS. Pharmacology of endogenous neuroactive steroids. Crit Rev Neurobiol 2003, 15(3-4):197-234.
49. Kelley SP, Alan JK, O'Buckley TK, Mennerick S, Krishnan K, Covey DF, Leslie Morrow A. Antagonism of neurosteroid modulation of native gamma-aminobutyric acid receptors by (3alpha,5alpha)-17-phenylandrost-16-en-3-ol. Eur J Pharmacol 2007, 572(2-3):94-101. 2098702, 17658511.
50. Harney SC, Frenguelli BG, Lambert JJ. Phosphorylation influences neurosteroid modulation of synaptic GABAA receptors in rat CA1 and dentate gyrus neurones. Neuropharmacology 2003, 45:873-883. 10.1016/S0028-3908(03)00251-X, 14529725.
51. Lambert JJ, Belelli D, Peden DR, Vardy AW, Peters JA. Neuroactive steroid modulation of GABAA receptors. Prog Neurobiol 2003, 71:67-80. 10.1016/j.pneurobio.2003.09.001, 14611869.
52. Boehm SL, Ponomarev I, Blednov YA, Harris RA. From gene to behavior and back again: new perspectives on GABAA receptor subunit selectivity of alcohol actions. Adv Pharmacol 2006, 54:171-2037.
53. Park-Chung M, Malayev A, Purdy RH, Gibbs TT, Farb DH. Sulfated and unsulfated steroids modulate γ aminobutyric acidA receptor function through distinct sites. Brain Res 1999, 830:72-87. 10.1016/S0006-8993(99)01381-5, 10350561.
54. Akk G, Bracamontes J, Steinbach JH. Pregnenolone sulfate block of GABAA receptors: mechanism and involvement of a residue in the M2 region of the α subunit. J Physiol (Lond) 2001, 532:673-684.
55. Mtchedlishvili Z, Kapur J. A presynaptic action of the neurosteroid pregnenolone sulfate on GABAergic synaptic transmission. Mol Pharmacol 2003, 64:857-864. 10.1124/mol.64.4.857, 2895321, 14500742.
56. Twede V, Tartaglia AL, Covey DF, Bamber BA. The neurosteroids dehydroepiandrosterone sulfate and pregnenolone sulfate inhibit the UNC-49 GABA receptor through a common set of residues. Mol Pharmacol 2007, 72(5):1322-9. 10.1124/mol.107.034058, 17715402.
57. Do Rego JL, Seong JY, Burel D, Leprince J, Vaudry D, Luu-The V, Tonon MC, Tsutsui K, Pelletier G, Vaudry H. Regulation of neurosteroid biosynthesis by neurotransmitters and neuropeptides. Front Endocrinol (Lausanne) 2012, 3:4. Epub 2012 Jan 24.
58. Guille C, Spencer S, Cavus I, Epperson CN. The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: implications for diagnosis and treatment. Epilepsy Behav 2008, 13(1):12-24. 10.1016/j.yebeh.2008.02.004, 18346939.
59. Kita A, Furukawa K. Involvement of neurosteroids in the anxiolytic-like effects of AC-5216 in mice. Pharmacol Biochem Behav 2008, 89(2):171-8. 10.1016/j.pbb.2007.12.006, 18201755.
60. Hardoy MC, Sardu C, Dell'osso L, Carta MG. The link between neurosteroids and syndromic/syndromal components of the mood spectrum disorders in women during the premenstrual phase. Clin Pract Epidemol Ment Health 2008, 4:3.
61. Eser D, Schüle C, Baghai TC, Romeo E, Rupprecht R. Neuroactive steroids in depression and anxiety disorders: clinical studies. Neuroendocrinology 2006, 84(4):244-54. 10.1159/000097879, 17159334.
62. Sundstrom Poromaa I, Smith S, Gulinello M. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Women Ment Health 2003, 6(1):23-41.
63. Miller MN, Miller BE. Premenstrual exacerbations of mood disorders. Psychopharmacol Bull 2001, 35(3):135-149.
64. Pisu MG, Serra M. Neurosteroids and neuroactive drugs in mental disorders. Life Sci 2004, 74:3181-3197. 10.1016/j.lfs.2003.12.002, 15094320.
65. Brambilla F, Biggio G, Pisu MG, Bellodi L, Perna GP, Bogdanovich-Djukic V, Purdy RH, Serra M. Neurosteroid secretion in panic disorder. Psychiatry Res 2003, 118:107-116. 10.1016/S0165-1781(03)00077-5, 12798975.
66. Strohle A, Romeo E, di Michele F, Pasini A, Hermann B, Gajewsky G, Holsboer F, Rupprecht R. Induced panic attacks shift γ-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch Gen Psychiatry 2003, 60:161-168. 10.1001/archpsyc.60.2.161, 12578433.
67. Uzunov DP, Cooper TB, Costa E, Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc Natl Acad Sci USA 1996, 93:12599-12604. 10.1073/pnas.93.22.12599, 38038, 8901628.
68. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998, 95(6):3239-3244. 10.1073/pnas.95.6.3239, 19726, 9501247.
69. Charalampopoulos I, Remboutsika E, Margioris AN, Gravanis A. Neurosteroids as modulators of neurogenesis and neuronal survival. Trends Endocrinol Metab 2008, 19(8):300-7. 10.1016/j.tem.2008.07.004, 18771935.
70. Bessa JM, Ferreira D, Melo I, Marques F, Cerqueira JJ, Palha JA, Almeida OF, Sousa N. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry 2009, 14(8):764-773. 739, 10.1038/mp.2008.119, 18982002.
71. Hardoy MC, Serra M, Carta MG, Contu P, Pisu MG, Biggio G. Increased neuroactive steroid concentrations in women with bipolar disorder or major depressive disorder. J Clin Psychopharmacol 2006, 26(4):379-84. 10.1097/01.jcp.0000229483.52955.ec, 16855455.
72. Féline A. Hyperthymic disorders. Encéphale 1993, 19(2):103-7.
73. Carta MG, Tondo L, Balestrieri M, et al. Sub-threshold depression and antidepressants use in a community sample: searching anxiety and finding bipolar disorder. BMC Psychiatry 2011, 11:164. 10.1186/1471-244X-11-164, 3206417, 21985128.
74. Frank E, Cyranowski JM, Rucci P, Shear MK, Fagiolini A, Thase ME, Cassano GB, Grochocinski VJ, Kostelnik B, Kupfer DJ. Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorder. Arch Gen Psychiatry 2002, 59(10):905-911. 10.1001/archpsyc.59.10.905, 12365877.
75. Cassano GB, Rucci P, Frank E, Fagiolini A, Dell'Osso L, Shear MK, Kupfer DJ. The mood spectrum in unipolar and bipolar disorder: arguments for a unitary approach. Am J Psychiatry 2004, 161(7):1264-1269. 10.1176/appi.ajp.161.7.1264, 15229060.
76. Carta MG, Hardoy MC, Garofalo A, Pisano E, Nonnoi V, Intilla G, Serra G, Balestrieri C, Chessa L, Cauli C, Lai ME, Farci P. Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. Clin Pract Epidemol Ment Health 2007, 23(3):22.
77. Pearson H. Hormone therapy: a dangerous elixir?. Nature. 2004, 431:500-501. 10.1038/431500a, 15457228.
78. Pinna G, Costa E, Guidotti A. Changes in brain testosterone and allopregnanolone biosynthesis elicit aggressive behavior. Proc Natl Acad Sci U S A 2005, 102(6):2135-40. Epub 2005 Jan 27, 10.1073/pnas.0409643102, 548579, 15677716.
79. Johansson AG, Nikamo P, Schalling M, Landén M. AKR1C4 gene variant associated with low euthymic serum progesterone and a history of mood irritability in males with bipolar disorder. J Affect Disord 2011, 133(1-2):346-51.
80. Johansson AG, Nikamo P, Schalling M, Landén M. Polymorphisms in AKR1C4 and HSD3B2 and differences in serum DHEAS and progesterone are associated with paranoid ideation during mania or hypomania in bipolar disorder. Eur Neuropsychopharmacol 2012, 22(9):632-640. 10.1016/j.euroneuro.2012.01.007, 22356824.
81. Fagiolini A, Dell'Osso L, Pini S, Armani A, Bouanani S, Rucci P, Cassano GB, Endicott J, Maser J, Shear MK, Grochocinski VJ, Frank E. Validity and reliability of a new instrument for assessing mood symptomatology: the Structured Clinical Interview for Mood Spectrum (SCI MOODS). Int J Meth Psych Res 1999, 8:71-81.
82. Huang MC, Wang YB, Chan CH. Estrogen-progesterone combination for treatment-refractory post-partum mania. Psychiatry Clin Neurosci. 2008, 62:126. 10.1111/j.1440-1819.2007.01782.x, 18289153.
83. Bowden CL. Anticonvulsants in bipolar disorders: current research and practice and future directions. Bipolar Disord 2009, 11(2):20-33.
84. Grunze HC. Anticonvulsants in bipolar disorder. J Ment Health 2010, 19(2):127-41. 10.3109/09638230903469186, 20433321.
85. Marx CE, Yuan P, Kilts JD, Madison RD, Shampine LJ, Manji HK. Neuroactive steroids, mood stabilizers, and neuroplasticity: alterations following lithium and changes in Bcl-2 knockout mice. Int J Neuropsychopharmacol. 2008, 11(4):547-52.
86. Chang JS, Ha KS, Young Lee K, Sik Kim Y, Min Ahn Y. The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. J Clin Psychiatry 2006, 67(3):461-7. 10.4088/JCP.v67n0318, 16649834.
87. Tohen M, Sutton VK, Calabrese JR, Sachs GS, Bowden CL. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J Affect Disord 2009, 116(1-2):43-50. 10.1016/j.jad.2008.11.003, 19054570.
88. Marx CE, Stevens RD, Shampine LJ, Uzunova V, Trost WT, Butterfield MI, Massing MW, Hamer RM, Morrow AL, Lieberman JA. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology. 2006, 31(6):1249-63.
89. Marx CE, Shampine LJ, Duncan GE, VanDoren MJ, Grobin AC, Massing MW, Madison RD, Bradford DW, Butterfield MI, Lieberman JA, Morrow AL. Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy?. Pharmacol Biochem Behav. 2006, 84(4):598-608. 10.1016/j.pbb.2006.07.026, 16962649.
90. Marx CE, Shampine LJ, Khisti RT, Trost WT, Bradford DW, Grobin AC, Massing MW, Madison RD, Butterfield MI, Lieberman JA, Morrow AL. Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. Pharmacol Biochem Behav. 2006, 84(4):609-17. 10.1016/j.pbb.2006.07.032, 16996120.
91. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079-88. Erratum in. Arch Gen Psychiatry. 2004, 61(2):176.
92. Brown E, Dunner DL, McElroy SL, Keck PE, Adams DH, Degenhardt E, Tohen M, Houston JP. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol. 2008, 11:1-10.
93. Arnold LM. Gender differences in bipolar disorder. Psychiatr Clin North Am. 2003, 26(3):595-620. 10.1016/S0193-953X(03)00036-4, 14563100.
94. Cabras PL, Hardoy MJ, Hardoy MC, Carta MG. Clinical Experience with gabapentin in patients with Bipolar or Scizoaffective Disorder. J Clin Psychiatry 1999, 60(4):245-248. 10.4088/JCP.v60n0408, 10221286.
95. Carta MG, Hardoy MC, Hardoy MJ, Grunze H, Carpiniello B. The clinical use of gabapentin in bipolar spectrum disorders. J Affect Disord. 2003, 75(1):83-91. 10.1016/S0165-0327(02)00046-0, 12781355.
96. Carta MG, Hardoy MC, Grunze H, Carpiniello B. The use of tiagabine in affective disorders. Pharmacopsychiatry 2002, 35(1):33-4. 10.1055/s-2002-19836, 11819159.
97. Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord. 2006, 8(1):15-27. 10.1111/j.1399-5618.2006.00276.x, 16411977.
98. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin bipolar disorder study group. Bipolar Disord. 2000, 2(3 Pt 2):249-55.
99. Suppes T, Chisholm KA, Dhavale D, Frye MA, Altshuler LL, McElroy SL, Keck PE, Nolen WA, Kupka R, Denicoff KD, Leverich GS, Rush AJ, Post RM. Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord. 2002, 4(5):283-9. 10.1034/j.1399-5618.2002.01201.x, 12479659.
100. Roy Chengappa KN, Schwarzman LK, Hulihan JF, Xiang J, Rosenthal NR. Clinical affairs product support study-168 investigators. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J Clin Psychiatry 2006, 67(11):1698-706. 10.4088/JCP.v67n1105, 17196048.
101. Elger CE, Schmidt D. Modern management of epilepsy: a practical approach. Epilepsy Behav. 2008, 12(4):501-39. 10.1016/j.yebeh.2008.01.003, 18314396.
102. Carta MG, Kovess V, Hardoy MC, Brugha T, Fryers T, Lehtinen V, Xavier M. Psychosocial wellbeing and psychiatric care in the European Communities: analysis of macro indicators. Social Psychiatry and Psychiatric Epidemiology 2004, 39(11):883-92. 10.1007/s00127-004-0871-0, 15549240.
103. Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M. Translocator protein(18kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat. Rev. Drug Discov. 2010, 9:971-9. 10.1038/nrd3295, 21119734.
104. Tokuda K, O' Dell KA, Izumi Y, Zorumski CF. Midazolam inhibits hippocampal long-term potentiation and learning through dual central and peripheral benzodiazepine receptor activation and neurosteroidogenesis. J. Neurosci 2010, 30:16788-16795. 10.1523/JNEUROSCI.4101-10.2010, 3073626, 21159950.